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The malaria parasite Plasmodium falciparum has at least five putative histone deacetylase (HDAC) enzymes,
which have been proposed as new antimalarial drug targets and may play roles in regulating gene transcrip-
tion, like the better-known and more intensively studied human HDACs (hHDACs). Fourteen new compounds
derived from L-cysteine or 2-aminosuberic acid were designed to inhibit P. falciparum HDAC-1 (PfHDAC-1)
based on homology modeling with human class I and class II HDAC enzymes. The compounds displayed highly
potent antiproliferative activity against drug-resistant (Dd2) or drug sensitive (3D7) strains of P. falciparum
in vitro (50% inhibitory concentration of 13 to 334 nM). Unlike known hHDAC inhibitors, some of these new
compounds were significantly more toxic to P. falciparum parasites than to mammalian cells. The compounds
inhibited P. falciparum growth in erythrocytes at both the early and late stages of the parasite’s life cycle and
caused altered histone acetylation patterns (hyperacetylation), which is a marker of HDAC inhibition in
mammalian cells. These results support PfHDAC enzymes as being promising targets for new antimalarial
drugs.
Malaria is one of the most significant infectious diseases of
the 21st century, resulting in an estimated 500 million infec-
tions and 2 million deaths annually, predominantly in sub-
Saharan Africa and Asia (32). There is currently no effective
vaccine against malaria, and mosquito control and chemother-
apy are the main approaches to the prevention and treatment
of this disease. Unfortunately, the principal malarial protozoan
parasite in humans, Plasmodium falciparum, has become in-
creasingly resistant to currently used drugs (27, 28). Therefore,
there is an urgent need for new antimalarial agents that act on
different parasite targets, as they have the potential to combat
resistance. The histone deacetylases (HDACs) of P. falciparum
(PfHDACs) may be promising targets for new classes of anti-
malarial drugs (6, 20).
HDAC enzymes play crucial roles in modulating the chro-
matin structure in eukaryotes through regulating the degree of
“packaging/unpackaging” of chromosomal DNA for transcrip-
tion (3). Histone proteins form the fundamental core unit of
chromatin and are reversibly acetylated on the ε-amino side
chain of several of their lysine residues. Together with other
modifications (e.g., methylation), interactions between acety-
lated/deacetylated histones and DNA are crucial for gene ex-
pression (31). The degree of histone acetylation, regulated by
the opposing action of histone acetyltransferases and HDACs, is
critical for transcriptional control. HDACs also regulate gene
expression through the acetylation of other proteins such as
transcription factors (13). There are at least 18 HDAC genes in
the human genome: human HDAC-1 (hHDAC-1), hHDAC-2,
hHDAC-3, and hHDAC-8 belong to class I hHDACs, and
hHDAC-4, hHDAC-5, hHDAC-6, hHDAC-7, hHDAC-9, and
hHDAC-10 are class II hHDACs, while SIRT1 to SIRT7 are
members of the class III HDAC Sir2 (silent information regulator
2) protein family (16). hHDAC-11 has recently been classified as
a separate class (reviewed in reference 40).
Two of five putative deacetylase-encoding genes in P. falcip-
arum have now been partially characterized: PfHDAC-1 (20)
(PlasmoDB accession number PFI1260c) and PfSir2 (7, 11)
(PlasmoDB accession number PF13_0152). PfHDAC-1 has ho-
mology with the class I RPD3 family of HDACs from human
(54% sequence identity), chicken, frog, and Saccharomyces
cerevisiae (20). The PfSir2 homologue (30) has been shown to
bind telomeres and cause gene silencing but over larger dis-
tances than yeast Sir2 (55 kb, versus 3 kb in yeast) (11, 29).
PfSir2, via histone deacetylation, appears to be involved in the
silencing of a multigene family encoding P. falciparum variant
surface antigens (var genes) (11). Recent annotation of the
complete genome of P. falciparum has revealed additional
putative HDAC-encoding gene homologues, although these
have not been characterized (PlasmoDB accession numbers
PF14_0690, PF10_0078, and PF14_0489) (20).
The fungal metabolites apicidin and trichostatin A (TSA) (4,
5) and recent analogues have been shown to inhibit P. falcip-
arum growth and to cause the hyperacetylation of histones in
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vitro (6). These compounds are, however, readily metabolized
in vivo into inactive forms. Other less potent, but more bio-
available, inhibitors of hHDACs also have antimalarial activity
against P. falciparum at low micromolar concentrations (e.g.,
azelaic bishydroxamic acid [50% inhibitory concentration
{IC50}, 3.2 to 4.9 M]) and suberohydroxamic acid [SBHA]
[IC50, 0.8 to 1.3 M]) (1), with SBHA being apparently cyto-
static against the acute rodent malaria organism Plasmodium
berghei in mice (1). Although all of these compounds non-
selectively inhibit the growth of malarial parasites, cancer
cells, and mammalian cells in vitro (12, 21), their antipara-
sitic activities support the idea that PfHDACs may be valu-
able new antimalarial targets (4, 5).
In this paper, we describe the properties of new compounds
that have been identified with the aid of a homology model to
have micromolar-to-nanomolar affinity for the active site of
PfHDAC-1. They were examined for (i) antiproliferative ac-
tivity against drug-resistant (Dd2) and drug-sensitive (3D7)
strains of P. falciparum compared with toxicity to human cells,
(ii) differential effects on parasite growth at specific stages in
the parasite intraerythrocytic life cycle, and (iii) the capacity to
induce the hyperacetylation of P. falciparum histones. The an-
timalarial activities were also compared in vitro with known
compounds reported to specifically inhibit mammalian
HDACs of classes I, I/II, II and III. The new compounds
displayed enhanced antiproliferative potencies against P. fal-
ciparum (IC50, 3 to 339 nM) and higher selectivities in killing
parasites over mammalian cells (up to 100-fold). These impres-
sive in vitro potencies and selectivities suggest a promising new
approach to combating malaria and provide powerful new
tools for studying the functions of HDACs in P. falciparum.
MATERIALS AND METHODS
Materials. TSA and sirtinol were purchased from Sigma (St. Louis, MO). The
synthesis and characterization of the various hydroxamate derivatives of 2-amino-
suberic acid and cysteine have been reported elsewhere in connection with their
antitumor activities (12, 21). The HDAC-1 inhibitor MS-275 (26) was obtained
commercially from Calbiochem (EMD Chemicals Inc., Darmstadt, Germany),
HDAC-6 inhibitor 2664-12 was synthesized and characterized in-house as de-
scribed previously (34). All compounds were prepared as stocks in 100% di-
methyl sulfoxide (DMSO) at 5 to 20 mM and stored at 20°C. TSA was ali-
quoted and stored at 80°C. Human red blood cells (O positive) and sera were
provided by the Brisbane Red Cross Blood Service. Polyclonal rabbit anti-acetyl
histone H4 sera were purchased from Upstate (Millipore, Billerica, MA). These
antisera recognize tetra-acetylated H4 and cross-react with P. falciparum H2A
(25). Anti-rabbit horseradish peroxidase-conjugated antisera were purchased
from Zymed (Invitrogen Corp., Carlsbad, CA). Calf thymus histones were pur-
chased from Sigma (St. Louis, MO).
Homology model of PfHDAC-1. The 499-amino-acid sequence of PfHDAC-1
(PlasmoDB accession number PFI1260c) was submitted to UniProt (http://www
.ebi.uniprot.org/index.shtml), and a WU-Blast2 search of the Protein Data Bank
(PDB) was performed. Twelve proteins with 30% identity with PfHDAC-1
were identified. Four of these sequences were too short for useful homology
modeling, leaving a yeast HDAC-like protein (HDLP) (PDB accession numbers
1C3R, 1C3S, and 1C3P, all with 31% identity) and hHDAC-8 (accession num-
bers 1T64, 1T67, 1T69, 1VKG, and 1W22, all with 41% identity). These crystal
structures were used as templates for the construction of a homology model
using the comparative protein structure modeling program Modeller (http://www
.salilab.org/modeler/) within InsightII (Accelrys Software Inc.). The PfHDAC-1
amino acid sequence and template crystal sequences were read into InsightII,
and the multiple sequence alignment was used to predict structurally conserved
regions and loop regions of the target PfHDAC-1 sequence. The aligned se-
quences were used in Modeller to create a homology model. Parameters were set
to cut overhanging amino acids and generate a high level of accuracy for the
model, with each loop region being modeled three times and with the final model
containing the loop of best fit. Finally, the homology model of PfHDAC-1 was
checked using ProCheck (22) and had an overall average G factor of 0.2
(acceptable scores were 0.5). The structure was used for flexible ligand
docking studies with GOLD.
Ligand docking. InsightII was used to add the catalytic zinc atom to the
homology model of PfHDAC-1 and to construct ligands 1 to 14 and TSA. GOLD
(CCDC Software Limited), a genetic algorithm for protein-ligand docking, was
used to flexibly dock ligands into the active site of PfHDAC-1 using standard
parameters. One distance constraint (1.5 to 3.0 Å) was set between the ligand
hydroxamic acid hydroxyl oxygen and the zinc atom of PfHDAC-1. GOLD
generated 10 docked conformations for each ligand and ranked their relative
binding conformations, and Ludi was used to qualitatively assess ligand fit to the
active site of PfHDAC-1.
P. falciparum in vitro growth inhibition assays. P. falciparum Dd2 (39) and
3D7 (38) were cultured in vitro with O-positive human erythrocytes in RPMI
1640 medium (Gibco BRL) supplemented with 10% heat-inactivated human
serum, as previously described (36). Growth inhibition of synchronous ring-stage
parasitized erythrocytes starting at 0.25% parasitemia and 2.5% hematocrit was
assessed using [3H]hypoxanthine incorporation (1). Chloroquine was included in
all assays as an internal control. The final concentrations of each compound
required to inhibit [3H]hypoxanthine incorporation by 50% (IC50), in compari-
son to DMSO controls, was determined by linear interpolation of inhibition
curves as described previously (18). Each assay was performed in triplicate wells
on at least four separate occasions. Data are presented as IC50s ( standard
deviations). To calculate the statistical significance (P  0.05) of IC50 values
between strains, a two-tailed Student’s t test (two-sample equal variance) was
carried out.
Stage-specific activity assays. The effect of TSA and compounds 9 and 14 on
the growth and development of P. falciparum blood-stage parasites was deter-
mined by exposing synchronous-ring-, trophozoite-, or schizont-stage P. falcip-
arum Dd2-infected erythrocytes to 200 nM TSA or 50 and 200 nM of compound
9 or 14. Starting parasitemias varied from 0.2 to 1.0% depending on the exper-
iment. In each case, parasitemia was monitored at different intervals over 2 to 4
days via microscopic examination of Giemsa-stained thin smears. Percent para-
sitemia was determined for at least 1,000 erythrocytes (counted by two indepen-
dent persons) at each time point and compared to matched DMSO (0.05%)-
treated vehicle controls. Three independent experiments were carried out
(representative results are shown). Mean parasitemias at 48 h after beginning
treatment for each treatment group were tested using analysis of variance with
the experimental replicate included as a covariate. Significance was determined
to be a P value of 0.01.
Histone hyperacetylation. The effect of test compounds on histone acetylation
status was determined by incubating 3 109 late-trophozoite-stage Dd2-infected
erythrocytes with different concentrations of drug, or vehicle (0.01% DMSO), for
3.5 h at 37°C. Cells were lysed in 0.15% saponin (Sigma) and then washed
extensively in phosphate-buffered saline (PBS) (pH 7.4) before preparation of
histones (as described in instructions provided with a commercially purchased
anti-acetyl histone H4 antiserum [Upstate]). Briefly, parasite pellets were resus-
pended in 5 volumes of lysis buffer (10 mM HEPES [pH 7.9], 1.5 mM NaCl, 10
mM KCl), and a final concentration of 0.5 M HCl was added. Acid extraction was
carried out on ice for 1.5 h, with frequent agitation. Acid-insoluble proteins were
pelleted, and the acid-soluble protein fraction was precipitated in 1 volume of
acetone at 20°C overnight. Acid-soluble proteins were pelleted, air dried, and
resuspended in 50 l 1 sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) sample buffer. Histone extracts (approximately 6  108
parasites per lane) were resolved by 15% SDS-PAGE and subjected to silver
staining to confirm equal loading. To detect changes in acetylation patterns
following treatment with compound, SDS-PAGE-separated samples were trans-
ferred onto a polyvinylidene difluoride membrane (Roche) at 80 V for 1 h in 25
mM Tris–0.2 M glycine–20% methanol. Membranes were blocked in PBS con-
taining 3% skim milk powder for at least 1 h before adding anti-acetyl H4 histone
antibody (1:2,000 dilution in PBS–3% skim milk powder; Upstate) and incubat-
ing the solution for 2 h at room temperature. Following three washes in deion-
ized water, membranes were incubated for 1 h in goat anti-rabbit horseradish
peroxidase (1:5,000 dilution in PBS–3% skim milk powder; Zymed). Membranes
were again washed, and signal was detected with ECL (GE Healthcare, United
Kingdom) and autoradiography.
RESULTS
Effect of inhibitors of hHDACs on P. falciparum growth in
vitro. To benchmark this study, we first examined the antipro-
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liferative activities of known inhibitors of class I, class II, and
class III mammalian HDACs in vitro against cultured P. falcip-
arum-infected erythrocytes using an isotopic microtest. There
are few compounds for which selective action on mammalian
HDACs has been reported. The compounds TSA, suberoyl-
anilide hydroxamic acid (SAHA), and SBHA are inhibitors of
class I and class II hHDACs and were previously shown to
inhibit the growth of drug-resistant (Dd2) and drug-sensitive
(3D7) strains of P. falciparum at low micromolar concentra-
tions (1, 4–6) (Table 1), with SBHA being the least potent but
displaying a better selectivity index for killing parasites over
normal cells than did TSA and SAHA (Table 1). Here, we
demonstrate only modest antiproliferative activity (IC50 of 8 to
20 M) against P. falciparum in vitro for compounds known to
be specific inhibitors of hHDAC enzymes of class I (MS-275),
class II (2664-12), and class III (sirtinol) (Table 1). MS-275
selectively inhibits hHDAC-1 (26), and compound 2664-12 is a
thiolate analogue of an hHDAC-6-selective substrate and is a
40-fold-more-potent inhibitor of hHDAC-6 than hHDAC-1 or
hHDAC-4 in enzyme assays (34), while sirtinol is a selective
inhibitor of class III mammalian HDACs (15). One of our
objectives was to rationally select HDAC inhibitors that might
more potently inhibit PfHDACs.
Sequence and structure of the PfHDAC-1 protein. To de-
velop a homology structural model of PfHDAC-1, we first
compared the sequence of PfHDAC-1 with those of mamma-
lian HDACs. hHDAC-1 (61% sequence identity), HDLP
(1c3p.pdb) (32% sequence identity), and hHDAC-8 (40% se-
quence identity) have a well-conserved core deacetylase amino
acid sequence in common with PfHDAC-1. Using sequence
alignment analysis and crystal structures of HDLP and
hHDAC-8 (class I HDACs), we developed a putative structure
for PfHDAC-1. ClustalW (35) was used to align the sequences
(see Table S1 in the supplemental material). The active-site
Zn2 binding residues in PfHDAC-1 (D174, D262, and H176)
were identical in all four proteins. Catalytically important res-
idues identified in HDLP and hHDAC-8 crystal structures
were also identical in the four proteins (e.g., H138, H139,
D172, D179, and Y301 in PfHDAC-1). The active-site wall
from the entrance to the catalytic zinc is lined with identical
TABLE 1. Comparative antiproliferative potencies against P. falciparum in vitro for known inhibitors of class I, II, and III hHDAC enzymes
HDAC class Inhibitor Structure
P. falciparum IC50 (M)d Mammalian cell
toxicity IC50
(M)e
Selectivity indexf
CQ resistant CQ sensitive CQ resistant CQ sensitive
Ia MS-275 7.8 8.3 20 2.6 2.4
I and IIb TSA 0.008 0.011 0.2 25 18
SBHA 0.8 1.3 300 375 230
SAHA 1.78 0.94 20 11 21
IIc HDAC-6 inhibitor 19.9 15.2 ND ND ND
III Sirtinol 9.1 12.9 25 2.7 1.9
CQ 0.293 0.012
a See reference 17.
b See references 1 and 24.
c See reference 34.
d P. falciparum line Dd2 is chloroquine (CQ) resistant; P. falciparum line 3D7 is chloroquine sensitive. For SAHA, P. falciparum chloroquine-resistant and -sensitive
lines were W2 and D6, respectively (24).
e Mammalian cell toxicity was tested against neonatal foreskin fibroblast cells for TSA (26), SBHA (2), and sirtinol (our unpublished results); against Vero cells for
SAHA (24); and against WI-38 lung fibroblasts and breast fibroblasts for MS-275 (37).
f Selectivity calculated as the difference between P. falciparum and mammalian cell toxicity IC50 values (IC50 of mammalian cells/IC50 of P. falciparum). ND, not
determined.
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hydrophobic residues (G147, F148, H176, F203, and Y301 in
PfHDAC-1), while PfHDAC-1 Leu269 was conservatively sub-
stituted by Met in hHDAC-8.
Sequence alignment of the loop 1 region of PfHDAC-1
(residues 15 to 30), hHDAC-1, and HDLP show good residue
conservation, whereas hHDAC-8 has a large insert, P22 to
C28, that appeared to produce a longer loop 1, although the
crystal structures of HDLP and hHDAC-8 showed the oppo-
site (9, 33). HDLP has a longer loop 1 due to the insertion of
HDLP residues H21 and P22 that also appear in homologous
regions of PfHDAC-1 and hHDAC-1 but not in hHDAC-8.
Therefore, it was expected that PfHDAC-1 loop 1 would be
more similar to that of HDLP. Loop 2 of the PfHDAC-1
sequence at N91 to G103 appears to be longer than those of
the other proteins. PfHDAC-1 loop 2 has a two-residue insert,
at A95 and T96, relative to hHDAC-1 and hHDAC-8. It is also
one residue longer than the HDLP sequence, with A95 miss-
ing. PfHDAC-1 loop 2 potentially crowds the area around the
active-site surface. Loop 5 of PfHDAC-1 at G200 to D211 is
less conserved overall, with exceptions being residues F203 and
P204, which are either a part of the hydrophobic tunnel or
adjacent to it. PfHDAC-1 and hHDAC-1 both have two dele-
tions relative to HDLP and one deletion relative to hHDAC-8.
This implies a smaller loop region that is more open at the
active site.
The homology structure has a relatively open binding site
and appears to have at least three binding pockets at the
surface entrance to the zinc-bound groove (Fig. 1). Using
GOLD (19), compounds 1 to 14 (see below) were flexibly
docked into the active site of the PfHDAC-1 homology model;
the highest-ranking conformation of inhibitors 8 and 13 is
shown in Fig. 1. The compounds had predicted binding affin-
ities of 1 M to 1 nM for PfHDAC-1, suggesting that they
would inhibit the enzyme.
Antimalarial efficacy of new HDAC inhibitors. Fourteen
nonpeptidic compounds (compounds 1 to 14) derived from
cysteine or 2-aminosuberic acid (Fig. 2) were examined for
toxicity against a drug-resistant (Dd2) and/or a drug-sensitive
(3D7) P. falciparum line in vitro. They were found to exhibit
IC50s against strain Dd2 ranging from 33 to 339 nM (Tables 2
and 3). With the exception of compound 10 (Dd2 IC50 of 334
nM), the hydroxamates derived from 2-aminosuberic acid were
generally more potent (IC50 of 33 to 105 nM) (Table 3) than
those derived from cysteine (IC50 of 48 to 339 nM) (Table 2).
This represents up to a 100-fold increase in activity com-
pared to that of SBHA (Table 1), which was tested in our
previous study (1). These values approach the low nanomolar
IC50 of TSA (1, 6). The selectivity of the 2-aminosuberic acid
derivatives for P. falciparum parasites over mammalian cells
(NNF) (12, 21) was also greater (up to 39-fold) than those
derived from cysteine (up to 13-fold) for the Dd2 strain. This
prompted us to test the 2-aminosuberic acid derivatives against
a second P. falciparum line, 3D7 (Table 3), which is sensitive to
chloroquine (Table 1) and other antimalarial drugs. IC50 val-
ues for 3D7 ranged from 13 to 91 nM, and with the exception
of compounds 7 (P 	 0.015) and 11 (P 	 0.016), these values
were not significantly different from those obtained for Dd2
(P  0.05).
Stage-specific effect of HDAC inhibitors on P. falciparum
growth in vitro. The effect of TSA and compounds 9 and 14 on
the growth and development of P. falciparum blood-stage par-
asites was determined by exposing ring-stage (18 h postinva-
sion), trophozoite-stage (26 h postinvasion), or schizont-
stage (38 h postinvasion) P. falciparum-infected erythrocytes
to each compound and monitoring parasitemia over 2 to 4
days. Ring-stage parasites were not able to mature normally
into trophozoites and schizonts, even after two complete
rounds of asexual reproduction in matched control cultures
(Fig. 3A). Similarly, trophozoite-stage parasites were not able
to mature into viable schizonts capable of producing invasive
merozoites as in untreated, matched control cultures (Fig. 3B).
When schizont-stage parasites at 38 h postinvasion were
treated with TSA or compound 9 or 14, some ring stages were
detected after 6 to 12 h but only at relatively low levels com-
pared to those of control cultures. In each case, (ring, tropho-
zoite, and schizont assays), a statistical analysis was carried out
on data collected at 48 h for three independent experiments,
and there was a significant reduction in parasitemia in TSA-,
compound 9-, and compound 14-treated groups compared to
controls (P  0.001).
Inhibitors of mammalian HDACs alter histone acetylation
in P. falciparum parasites. Two representative compounds
from the 2-aminosuberic acid series, compounds 9 and 14,
which display antimalarial potency at low nanomolar concen-
trations, were tested for their abilities to hyperacetylate his-
tones in P. falciparum parasites (Dd2). Histones prepared from
in vitro-cultured, infected erythrocytes treated with each com-
FIG. 1. Homology model of PfHDAC-1 active site (for the hydro-
phobicity surface, red is hydrophobic, and blue is hydrophilic) with
docked inhibitors 8 (orange, carbon atoms) and 13 (green, carbon
atoms; blue, nitrogen atoms; red, oxygen atoms), demonstrating three
potential binding pockets at the entrance to the active-site tunnel
containing the catalytic zinc atom (purple).
FIG. 2. Nonpeptidic compounds derived from 2-aminosuberic acid
(X is CH2) and L-cysteine (X is S) (see Tables 2 and 3 for R groups).
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pound (or controls) at various concentrations for 3.5 h were
analyzed by Western blotting using a commercial polyclonal
anti-tetra-acetyl histone H4 antibody (Upstate). The antibody
recognized a single predominant protein of13 kDa in control
parasites treated with the vehicle alone (DMSO), which cor-
responds to H4. The 13-kDa band comigrated with control
histones from calf thymus (Sigma). These bands represent the
natural histone acetylation state of the organism. Exposure of
P. falciparum parasites to TSA, compound 9, or compound 14
for 3.5 h resulted in altered parasite histone acetylation profiles
compared to those of matched controls, consistent with the
inhibition of PfHDAC activity (Fig. 4).
DISCUSSION
New, improved treatments for malaria are a high priority to
address the global problem of parasite resistance to existing
antimalarial drugs (8). HDAC enzymes in malarial parasites
may be a promising new target for antimalarial drug develop-
ment (6). HDAC inhibitors that can arrest growth and induce
differentiation and/or apoptotic cell death in various human
cancer cell lines also show antimalarial activity in vitro (1, 4–6,
24). These include compounds that are antiproliferative in
vitro against P. falciparum at low micromolar-to-nanomolar
concentrations but that are rapidly metabolized in vivo (e.g.,
TSA, apicidin, and trapoxin) (6) and others that are more
bioavailable but 10- to 1,000-fold less potent (e.g., azelaic
bishydroxamic acid, SAHA, and SBHA) (1). One of these
compounds, SAHA, which has modest potency against P.
falciparum (IC50 of 0.9 to 1.8 M) (24) was recently ap-
proved by the FDA for the treatment of T-cell lymphomas
(14). However, all these inhibitors have relatively poor se-
lectivity for P. falciparum versus normal mammalian cells (1,
4–6, 24) (Table 1).
Toward a better understanding of the role of HDAC inhib-
itors in P. falciparum, we first examined the antiproliferative
properties of known inhibitors of mammalian HDACs against
P. falciparum growth in vitro. We found that the specific in-
hibitors of classes I, II, and III did inhibit P. falciparum growth
but were less potent (IC50 of 8 to 20 M) than the more
broad-spectrum inhibitors of class I/II hHDAC enzymes (1
M) (Table 1). However, none of these known HDAC inhib-
itors were able to kill the malarial parasite at concentrations
much below those that were cytotoxic to normal human cells.
This prompted us to examine some structure-activity relation-
ships of alternative HDAC inhibitors with a view to identifying
compounds that were more potent and more selective in killing
P. falciparum than in killing normal human cells. We generated
a homology model of PfHDAC-1 (PlasmoDB accession num-
ber PFI1260c) by comparing its protein sequence with those of
structurally characterized HDACs. PfHDAC-1 shares 50%
amino acid homology with hHDACs, whereas the other puta-
tive class I/II PfHDAC homologues (PlasmoDB accession
numbers PF14_0690 and PF10_0078) have very limited se-
quence similarity (20). Furthermore, while PfHDAC-2 is pre-
dicted to be expressed in blood stages (www.plasmoDB.org)
and may still be a possible target of these compounds, PfHDAC-3
has been shown by mass spectroscopy to be present only in
gametocytes (10). The class III HDAC homologue PfSir2 is
unlikely to be a target of these compounds, as it can be genet-
TABLE 2. Comparative toxicities of cysteine derivatives against P. falciparum versus normal cellsa
Compound R1 R2 X IC50 of NFF (nM)(SD)
IC50 of Dd2 (nM)
(SD)
Selectivity
indexb
1 S 830 (90) 125 (35) 13
2 S 800 (200) 339 (219) 2
3 S 350 (70) 169 (149) 2
4 S 600 (100) 48 (43) 12
5 S 2,200 (200) 305 (209) 7
6 S 320 (50) 128 (146) 3
a R1, acid group side chain; R2, amine group side chain; X, atom or group on compound shown in Fig. 1.
b Selectivity index was calculated as the difference between P. falciparum and mammalian cells (neonatal foreskin fibroblast cell toxicity IC50 values/IC50 of P.
falciparum).
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ically disrupted in in vitro-cultured P. falciparum parasites (11).
Also, we observed no difference in antimalarial IC50 values for
compound 9 or 14 for this disruption mutant compared to
wild-type parasites (not shown).
By comparing amino acid sequences of PfHDAC-1 and
structurally characterized mammalian HDACs, we derived a
putative three-dimensional structure for PfHDAC-1 and
docked a range of broad-spectrum hHDAC inhibitors into the
active site. While quantitative predictions and rankings of li-
gand affinities in homology structures are notoriously unreli-
able, we did find that the compounds presented herein had
reasonably good molecular fits for the catalytic zinc-bound
active site of PfHDAC-1 and were predicted to have micro-
molar-to-nanomolar affinities for this enzyme. These qualita-
tive predictions were tested in vitro using a proliferative assay
for in vitro growth of the malarial parasite P. falciparum in
human erythrocytes (Tables 2 and 3), and compounds 7 to 14
in particular were found to have IC50 potencies of 13 to 334
nM against two strains.
The first category of HDAC inhibitor analogues, compounds
1 to 6, were based on a simple cysteine scaffold fused to ben-
zylamine at the C terminus and 4-butanoyl hydroxamate at the
S terminus and with different carboxylic acids at the N termi-
nus (Table 2). We have reported antitumor activity at nano-
molar concentrations for these inhibitors, which also cause the
hyperacetylation of mammalian histones, induce p21 expres-
sion, and revert tumor cell morphology to a more normal
phenotype (12, 21). The antimalarial IC50s for these com-
pounds ranged from 48 to 339 nM against a multidrug-resistant
(Dd2) P. falciparum line (Table 2). Selectivity indices for these
compounds ranged from2 to 13, which are similar to those of
SAHA (Table 1). The second class of HDAC inhibitors was
based on 2-aminosuberic acid, and we have previously found
them to be even more selective for tumor cells versus normal
cell lines than the compound series derived from L-cysteine
(21). We find this class of compounds to be highly potent
inhibitors of P. falciparum growth in vitro against multidrug-
resistant strain Dd2 (IC50, 33 to 334 nM) and drug-sensitive
TABLE 3. Comparative toxicities of 2-aminosuberic acid derivatives against two P. falciparum strains versus a normal cell linea
Compound R1 R2 X IC50 pf NFF(nM)
P. falciparum IC50 (nM)
(SD)b Selectivity index
c
Dd2 3D7 Dd2 3D7
7 CH2 2,200 105 (47) 29 (22) 21 76
8 CH2 190 41 (22) 22 (14) 5 9
9 CH2 1,240 39 (24) 15 (9) 32 83
10 CH2 5,860 334 (164) 91 (97) 17 64
11 CH2 4,010 102 (44) 34 (17) 39 118
12 CH2 1,260 63 (42) 34 (17) 20 37
13 CH2 570 71 (65) 19 (10) 8 30
14 CH2 337 33 (33) 13 (12) 10 26
a R1, R2, and X refer to variable groups on the compound shown in Fig. 1.
b IC50 values for 3D7 versus Dd2 were significantly different for compounds 7 (P 	 0.015) and 11 (P 	 0.016) but not for the remaining compounds (P  0.05).
c Selectivity index was calculated as the difference between P. falciparum and mammalian cells (neonatal foreskin fibroblast cell 
NFF toxicity IC50 values/IC50 of
P. falciparum).
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strain 3D7 (IC50, 13 to 91 nM) of P. falciparum and to display
good selectivity for P. falciparum versus a mammalian cell line
(Table 3).
In order to determine how these compounds act in the
parasite, we examined the effects of two representative com-
pounds from the 2-aminosuberic acid series (compounds 9 and
14) (Table 3) in comparison to those of TSA and untreated
controls. In stage-specific growth assays of in vitro-cultured P.
falciparum-infected erythrocytes, we found that ring-, tropho-
zoite-, and schizont-stage-infected erythrocytes were all signif-
icantly affected by exposure to these compounds. Some new
ring forms were observed in schizont cultures following expo-
sure to these compounds after 6 and 12 h but only at low levels.
The schizont preparations used were synchronous to a window
of about 4 h, and we speculate that the appearance of these
ring forms may result from a subpopulation of mature schiz-
onts close to bursting as compound was added and perhaps not
affected by these compounds. This will need to be confirmed
experimentally in the future. Taken together, these data sug-
gest that these compounds have a broad activity range on
asexual P. falciparum forms, although it remains to be seen
whether this corresponds to specific activity against PfHDAC
and/or a more general cytotoxicity.
We found that compounds 9 and 14 cause the hyperacety-
lation of P. falciparum histones, using an antibody that recog-
nizes tetra-acetylated H4 (and likely other histone species such
as H2A.Z) (23, 25). A similar histone acetylation pattern was
observed for controls treated with TSA. Given that hyperacety-
lation is a marker of HDAC inhibition in mammalian cells and
other organisms, including Plasmodium (6, 12, 21), this finding,
combined with our in silico modeling studies, suggests that
these compounds may act on PfHDAC(s).
Here, we have shown that a series of new compounds de-
rived simply from amino acids (L-cysteine or 2-aminosuberic
acid) show potent in vitro activity against P. falciparum-in-
fected erythrocytes. The best antimalarial activity obtained is
an order of magnitude greater than that previously reported
for synthetic HDAC inhibitors, and unlike most known HDAC
inhibitors, some of these compounds are significantly more
toxic to P. falciparum parasites than to normal cells. This en-
hanced selectivity in their killing action makes these inhibitors
attractive candidates for further development into antimalarial
drugs. Previously, we found that compound 1 had oral bioavail-
ability in rats (12), which augers well for the development of
these types of compounds as new antimalarials, with an appar-
ently different mechanism of action from that of established
antimalarial drugs. We have also shown that treatment of in-
fected erythrocytes with compounds 9 and 16 results in histone
hyperacetylation, which, together with our in silico molecular
fitting of these compounds to the active site of PfHDAC-1,
supports a mechanism of action involving the inhibition of
PfHDAC activity and underscores the potential value of this
class of enzymes as possible new pharmaceutical targets in the
malaria parasite.
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